Morgan Stanley’s Can-Fite BioPharma American Depositary Shares CANF Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3 | Sell |
1
-1
| -50% | -$4 | ﹤0.01% | 8245 |
|
|
2025
Q4 | $7 | Sell |
2
-626
| -100% | -$4.91K | ﹤0.01% | 8144 |
|
|
2025
Q3 | $7.77K | Buy |
628
+132
| +27% | +$2.01K | ﹤0.01% | 6967 |
|
|
2025
Q2 | $10.4K | Sell |
496
-665
| -57% | -$15.3K | ﹤0.01% | 6852 |
|
|
2025
Q1 | $34.4K | Sell |
1,161
-465
| -29% | -$14.8K | ﹤0.01% | 6394 |
|
|
2024
Q4 | $52.8K | Sell |
1,626
-907
| -36% | -$36.8K | ﹤0.01% | 6272 |
|
|
2024
Q3 | $102K | Sell |
2,533
-857
| -25% | -$45.9K | ﹤0.01% | 6005 |
|
|
2024
Q2 | $175K | Buy |
3,390
+600
| +22% | +$28.4K | ﹤0.01% | 5740 |
|
|
2024
Q1 | $124K | Sell |
2,790
-1,837
| -40% | -$76.7K | ﹤0.01% | 5906 |
|
|
2023
Q4 | $204K | Buy |
4,627
+2,977
| +180% | +$128K | ﹤0.01% | 5942 |
|
|
2023
Q3 | $87.5K | Sell |
1,650
-15
| -0.9% | -$849 | ﹤0.01% | 5953 |
|
|
2023
Q2 | $102K | Sell |
1,665
-5
| -0.3% | -$235 | ﹤0.01% | 5942 |
|
|
2023
Q1 | $76.5K | Buy |
1,670
+147
| +10% | +$10.6K | ﹤0.01% | 6112 |
|
|
2022
Q4 | $187K | Sell |
1,523
-78
| -5% | -$12.1K | ﹤0.01% | 5693 |
|
|
2022
Q3 | $247K | Sell |
1,601
-90
| -5% | -$15.6K | ﹤0.01% | 5629 |
|
|
2022
Q2 | $311K | Buy |
1,691
+170
| +11% | +$32.6K | ﹤0.01% | 5664 |
|
|
2022
Q1 | $377K | Buy |
1,521
+329
| +28% | +$76K | ﹤0.01% | 5572 |
|
|
2021
Q4 | $308K | Buy |
1,192
+209
| +21% | +$57.6K | ﹤0.01% | 5828 |
|
|
2021
Q3 | $326K | Buy |
983
+59
| +6% | +$23.2K | ﹤0.01% | 5737 |
|
|
2021
Q2 | $421K | Buy |
924
+525
| +132% | +$230K | ﹤0.01% | 5630 |
|
|
2021
Q1 | $197K | Buy |
399
+311
| +353% | +$135K | ﹤0.01% | 5667 |
|
|
2020
Q4 | $31K | Buy |
88
+63
| +252% | +$23K | ﹤0.01% | 6304 |
|
|
2020
Q3 | $9K | Buy |
25
+6
| +32% | +$2.5K | ﹤0.01% | 6295 |
|
|
2020
Q2 | $8K | Sell |
19
-32
| -63% | -$11.8K | ﹤0.01% | 6211 |
|
|
2020
Q1 | $13K | Sell |
51
-101
| -66% | -$38.7K | ﹤0.01% | 5947 |
|
|
2019
Q4 | $100K | Sell |
152
-101
| -40% | -$54.2K | ﹤0.01% | 5655 |
|
|
2019
Q3 | $104K | Sell |
253
-52
| -17% | -$27.6K | ﹤0.01% | 5436 |
|
|
2019
Q2 | $176K | Buy |
305
+168
| +123% | +$184K | ﹤0.01% | 5075 |
|
|
2019
Q1 | $358K | Buy |
137
+62
| +83% | +$217K | ﹤0.01% | 4750 |
|
|
2018
Q4 | $284K | Buy |
75
+11
| +17% | +$42.5K | ﹤0.01% | 5125 |
|
|
2018
Q3 | $247K | Buy |
64
+15
| +31% | +$56.2K | ﹤0.01% | 5353 |
|
|
2018
Q2 | $173K | Buy |
49
+12
| +32% | +$47.8K | ﹤0.01% | 5584 |
|
|
2018
Q1 | $161K | Buy |
37
+15
| +68% | +$82.9K | ﹤0.01% | 5554 |
|
|
2017
Q4 | $97K | Buy |
22
+8
| +57% | +$36.5K | ﹤0.01% | 5639 |
|
|
2017
Q3 | $70K | Buy |
14
+10
| +250% | +$51.5K | ﹤0.01% | 5677 |
|
|
2017
Q2 | $22K | Buy |
+4
| New | +$22K | ﹤0.01% | 6058 |
|
|
2017
Q1 | – | Sell |
-1
| Closed | -$6.07K | – | 6490 |
|
|
2016
Q4 | $6K | Sell |
1
-1
| -50% | -$7.01K | ﹤0.01% | 6249 |
|
|
2016
Q3 | $14K | Hold |
2
| – | – | ﹤0.01% | 6024 |
|
|
2016
Q2 | $14K | Buy |
+2
| New | +$16.9K | ﹤0.01% | 5957 |
|
|
2016
Q1 | – | Sell |
-81
| Closed | -$705K | – | 6575 |
|
|
2015
Q4 | $705K | Buy |
81
+53
| +189% | +$533K | ﹤0.01% | 4303 |
|
|
2015
Q3 | $347K | Buy |
+28
| New | +$188K | ﹤0.01% | 4809 |
|
|
2015
Q1 | – | Sell |
-1
| Closed | -$5K | – | 6555 |
|
|
2014
Q4 | $5K | Buy |
+1
| New | +$10K | ﹤0.01% | 6327 |
|
|
2014
Q2 | – | Sell |
-5
| Closed | -$80K | – | 6521 |
|
|
2014
Q1 | $80K | Buy |
5
+3
| +150% | +$51.3K | ﹤0.01% | 5537 |
|
|
2013
Q4 | $44K | Buy |
+2
| New | +$40.1K | ﹤0.01% | 5636 |
|
Other funds holding CANF
SM
HF
VF
Morgan Stanley's CANF Position: Q1 2026 in Review
Morgan Stanley reduced its Can-Fite BioPharma American Depositary Shares (CANF) stake by 50% in Q1 2026, selling an estimated $4 and leaving 1 share worth $3. The position accounts for ﹤0.01% of the portfolio, ranked #8245.
Morgan Stanley first reported a position in CANF in Q4 2013 and has held it in 44 quarters since. The position peaked at $705K in Q4 2015. 14 funds tracked by Wall St. Rank hold CANF as of Q1 2026.
- Morgan Stanley held 1 share of Can-Fite BioPharma American Depositary Shares worth $3 as of Q1 2026.
- Morgan Stanley sold 1 Can-Fite BioPharma American Depositary Shares share in Q1 2026, an estimated $4.
- Can-Fite BioPharma American Depositary Shares made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #8245 holding.
- Morgan Stanley first reported a position in Can-Fite BioPharma American Depositary Shares in Q4 2013 and has held it in 44 quarters since.
- Morgan Stanley's Can-Fite BioPharma American Depositary Shares position peaked at $705K in Q4 2015.
- 14 funds tracked by Wall St. Rank held Can-Fite BioPharma American Depositary Shares as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.